Previous 10 | Next 10 |
● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increase in Total Kidney Weight in Polycystic Kidney Disease ● CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”)...
CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, ann...
CALGARY, Alberta, Oct. 26, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...
• Chronically Increased Uric Acid Accelerates Structural and Functional Changes in Polycystic Kidney Disease • CALGARY, Alberta, Oct. 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TS...
CALGARY, Alberta, Oct. 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney ...
CALGARY, Alberta, Oct. 04, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney ...
XORTX Therapeutics ( NASDAQ: XRTX ) said it had completed the previously announced Type B Pre-phase 3 meeting with the U.S. Food and Drug Administration for XRx-008 program for the treatment of autosomal dominant polycystic kidney disease. Ahead of the meetin...
CALGARY, Alberta, Sept. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical development stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney dise...
CALGARY, Alberta, Sept. 01, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease is ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Chinnapong / Shutterstock.com Signify Health (NYSE: SGFY ) stock is climbing higher on Monday as investors react to reports that Amazon (NASDAQ: AMZN ) is bidding on the healthcare company . Acc...
News, Short Squeeze, Breakout and More Instantly...
XORTX Therapeutics Inc. Company Name:
XRTX Stock Symbol:
NASDAQ Market:
XORTX Therapeutics Inc. Website:
CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to anno...
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...